EFFICACY AND SAFETY OF TENELIGLIPTIN AS ADD-ON THERAPY TO CONVENTIONAL THERAPY IN INDIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS

  • PARMAR VINENDRA M Department of Pharmacology, L. M. College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.
  • GOSWAMI SUNITA S Department of Pharmacology, L. M. College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.

Abstract

Objective: Teneligliptin is a novel, highly selective dipeptidyl peptidase-4 inhibitor. The objective of the present study was to investigate the efficacy and safety of teneligliptin as add-on therapy in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled by conventional therapy (metformin/glimepiride) in India.


Methods: Clinical study protocol was approved by the Institutional Ethics Committee. T2DM patients (male/female) whose glycated hemoglobin (HbA1c) >7% were randomized to receive following group treatments, namely, Treatment A: Metformin/glimepiride plus add-on teneligliptin 20 mg and Treatment B: Metformin/glimepiride for 24 weeks. A pre-designed case report form was used to collect information from the prescribing physicians regarding the efficacy and safety of teneligliptin. Efficacy variables included change in plasma blood glucose (fasting and postprandial) and HbA1c from baseline to week 24. Treatment emergent adverse events were assessed.


Results: A total of 120 type 2 diabetes patients were analyzed. Teneligliptin as add-on therapy with metformin/glimepiride significantly reduced plasma glucose (HbA1c, fasting, and postprandial) concentration as compared to conventional therapy.


Conclusion: Add-on therapy with teneligliptin was found superior over conventional therapy in reducing plasma glucose concentration (fasting and postprandial) and HbA1c levels significantly in patients with T2DM. Further, it was found effective and well tolerated in Indian patients with T2DM who are inadequately controlled with conventional therapy.

Keywords: Teneligliptin, DDP-4 inhibitor, Glycated hemoglobin, Type 2 diabetes mellitus

References

1. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol 2016;12:357-70.
2. Nikhra V. Exploring complexities of T2DM: Insulin signaling, resistance and deficiency, metabolic links, sexual dimorphism and endocrine disruptors. Res Med Eng Sci 2018;5:1-10.
3. Ramachandran A, Das AK, Joshi SR, Yajnik CS, Shah S, Kumar KM. Current status of diabetes in India and need for novel therapeutic agents. J Assoc Physicians India 2010;58:7-9.
4. Aschner P. New IDF clinical practice recommendations for managing Type 2 diabetes in primary care. Diabetes Res Clin Pract 2017;132:169-70.
5. Gupta CN, Raghavan V, Sen S, Kothari S. Role of teneligliptin in rural India as add-on third drug in patients with Type 2 diabetes mellitus. Int J Adv Med 2017;4:401-5.
6. Riddle MC, Bakris G, Blonde L, Boulton AJ, D’alessio D, De Groot M, et al. Standard medical care in diabetes 2018. Diabetes Care 2018;41:S119-25.
7. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of Type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2016;9:251-60.
8. Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al. Oral and Injectable (Non-insulin) Pharmacological Agents for Type 2 Diabetes. South Dartmouth, MA: MDText.com, Inc.; 2019.
9. Wang CY, Neil DL, Home P 2020 vision-an overview of prospects for diabetes management and prevention in the next decade. Diabetes Res Clin Pract 2018;143:101-12.
10. Indian Council of Medical Research. ICMR Guidelines for Management of Type 2 Diabetes. Pharmacological Treatment For Diabetes. New Delhi: Indian Council of Medical Research; 2005. p. 16-31.
11. Snehalatha C, Priscilla S, Nanditha A, Arun R, Satheesh K, Ramachandran A, et al. Metformin in prevention of Type 2 diabetes. J Assoc Physicians India 2018;66:60-3.
12. Kim Y, Kang ES, Jang HC, Kim DJ, Oh T, Kim ES, et al. Teneligliptin versus sitagliptin in Korean patients with Type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2018;2018:1-9.
13. Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the hbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: A systematic review and meta-analysis. Diabetes Obes Metab 2014;16:900-9.
14. Mohammed R, Ahmed I, Banu A. Efficacy of teneligliptin in Type 2 diabetes mellitus. Int J Res Med Sci 2016;4:4607-10.
15. Kishimoto M. Teneligliptin: A DPP-4 inhibitor for the treatment of Type 2 diabetes. Diabetes Metab Syndr Obes 2013;6:187-95.
16. Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4- [4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2- ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. Bioorg Med Chem 2012;20:5705-19.
17. Nakamaru Y, Hayashi Y, Ikegawa R, Kinoshita S, Perez Madera B, Gunput D, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica 2014;44:242-53.
18. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on Type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 2009;15:540-59.
19. Yesudian CA, Grepstad M, Visintin E, Ferrario A. The economic burden of diabetes in India: A review of the literature. Global Health 2014;10:80.
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
21. Kadowaki T, Kondo K, Sasaki N, Miyayama K, Yokota S, Terata R, et al. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with Type 2 diabetes mellitus: A 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother 2017;18:1291-300.
22. Chandra P, Gogate B, Gogate P, Thite N, Mutha A, Walimbe A, et al. Economic burden of diabetes in urban Indians. Open Ophthalmol J 2014;8:91-4.
23. Joshi S, Jadhav V, Kadam V. Exotic fruits and vegetable food as nutritional supplement for diabetes, obesity and metabolic diseases. Int J Curr Pharm Res 2018;10:51-5.
24. Li X, Huang X, Bai C, Qin D, Cao S, Mei Q, et al. Efficacy and safety of teneligliptin in patients with Type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2018;9:449.
25. Bajaj S. RSSDI clinical practice recommendations for the management of Type 2 diabetes mellitus 2017. Int J Diabetes Dev Ctries 2018;38:1-15.
26. Takeda K, Sawazaki H, Takahashi H, Yeh YS, Jheng HF, Nomura W, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice. FEBS Open Bio 2018;8:1782-93.
27. Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Yoshida K, Kiuchi S, et al. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in zucker diabetic fatty rats. J Pharmacol Sci 2015;127:456-61.
28. Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with Type 2 diabetes mellitus: A 16- week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab 2015;17:309-12.
29. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 2014;16:418-25.
30. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with Type 2 diabetes mellitus. J Diabetes Investig 2013;4:576-84.
31. Gallwitz B, Haring HU. Future perspectives for insulinotropic agents in the treatment of Type 2 diabetes-DPP-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2010;12:1-11.
32. Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: Systematic review and meta-analysis. BMJ 2016;353:i2231.
33. Moon MK, Hur KY, Ko SH, Park SO, Lee BW, Kim JH, et al. Combination therapy of oral hypoglycemic agents in patients with Type 2 diabetes mellitus. Diabetes Metab J 2017;41:357-66.
34. Wu S, Chai S, Yang J, Cai T, Xu Y, Yang Z, et al. Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in Type 2 diabetes: A systematic review and network meta-analysis. Clin Ther 2017;39:1780-9.
Statistics
654 Views | 240 Downloads
Citatons
How to Cite
PARMAR VINENDRA M, and GOSWAMI SUNITA S. “EFFICACY AND SAFETY OF TENELIGLIPTIN AS ADD-ON THERAPY TO CONVENTIONAL THERAPY IN INDIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 12, Oct. 2019, pp. 116-20, doi:10.22159/ajpcr.2019.v12i12.35952.
Section
Original Article(s)